Miltenyi Biotec
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach
Germany
November 4–5, 2025 | Miltenyi Biotec, Bergisch Gladbach, Germany
Take a look below at the recorded sessions of the highly successful MACS Cell and Gene Therapy Days 2025 held in November, 2025 at Miltenyi Biotec HQ in Germany.
Miltenyi Biotec
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach
Germany
November 4, 2025 | 11:30 a.m. – 9:00 p.m.
November 5, 2025 | 8:30 a.m. – 2:30 p.m.
November 4, 2025 | 11:30 p.m. – 9:00 p.m.
November 5, 2025 | 8:30 a.m. – 2:30 p.m.
DAY 1
November 4, 2025
11:30 a.m.–
1:00 p.m.
Registration and lunch
1:00 p.m.–
3:00 p.m.
Next frontiers in CGT: new indications and therapeutic strategies
Latest clinical developments in CAR T cell therapy of autoimmunity
Speaker: Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany
Rapid succession of graft engineering and CAR T therapies facilitated by PoC manufacturing
Speaker: Wing Leung, MD, KK Women's and Children's Hospital, Singapore
Developing stem cell gene therapy for rare inflammatory disorders
Speaker: Despina Eleftheriou, MD, UCL GOS Institute of Child Health, London, United Kingdom
Navigating pre-GMP and GMP-core development: lessons from the Swedish/Norwegian experience
Speaker: Anna Pasetto, PhD, Oslo University Hospital, Center for Advanced Cell Therapy (ACT), Oslo, Norway
3:00 p.m.–
3:30 p.m.
Break
3:30 p.m.–
4:30 p.m.
Panel discussion
Moderator: Rene Meißner, Miltenyi Biotec, Germany
Panelists:
Franco Locatelli, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany
Wing Leung, MD, KK Women's and Children's Hospital, Singapore
Despina Eleftheriou, MD, UCL GOS Institute of Child Health, London, United Kingdom
Anna Pasetto, PhD, Oslo University Hospital, Center for Advanced Cell Therapy (ACT), Oslo, Norway
4:30 p.m.–
7:30 p.m.
Company tours and networking
7:30 p.m.–
9:00 p.m.
Dinner
9:00 p.m.
Bus departure to hotel
DAY 2
November 5, 2025
8:30 a.m.–
9:00 a.m.
Keynote lecture
The long journey of CAR T cells: from hematology to oncology and autoimmune disorders
Speaker: Franco Locatelli, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
9:00 a.m.–
10:30 a.m.
PoC manufacturing of CGT - experiences around the globe
Academic PoC CAR T in Canada: opportunities and challenges getting to market
Speaker: Natasha Kekre, MD, Ottawa Hospital Research Institute, Ottawa, Canada
IL-18-enforced CAR T cell therapy for solid tumors
Speaker: Claudia Rossig, MD, University Children´s Hospital, Münster, Germany
Outcomes of low-cost, point-of-care manufactured CAR T cell therapy for B cell acute leukemia and non-hogkin lymphoblastic lymphoma in Vietnam
Speaker: Nguyen Thanh Liem, MD, Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
PoC manufacturing of CAR T therapy in Slovenia
Speaker: Matjaz Sever, MD, University Clinical Center Ljubljana, Ljubljana, Slovenia
10:30 a.m.–
10:45 a.m.
Workshop introduction
10:45 a.m.–
11:00 a.m.
Transition break
11:00 a.m.–
12:00 p.m.
Workshop – PoC manufacturing and analytics
12:00 p.m.–
1:00 p.m.
Lunch
1:00 p.m.–
2:00 p.m.
Workshop summary and panel discussion
Moderator: Cristina Conforti Andreoni, PhD, Miltenyi Biotec, Germany
Panelists:
Natasha Kekre, MD, Ottawa Hospital Research Institute, Ottawa, Canada
Claudia Rossig, MD, University Children´s Hospital, Münster, Germany
Nguyen Thanh Liem, MD, Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
Matjaz Sever, MD, University Clinical Center Ljubljana, Ljubljana, Slovenia
Laura Palau López, Hospital Clínic de Barcelona, Barcelona, Spain
2:00 p.m.–
2:30 p.m.
Transforming patient access through PoC manufacturing and analytics – a Miltenyi Biotec perspective
Speaker: Joe Thuan Lim, Miltenyi Biotec, Germany
2:30 p.m.
Closing and departure
Speaker: Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany
Since the first success of CD19 CAR T cells in treating systemic lupus erythematosus (SLE) more than four years ago, the field of CAR T cells outside of malignant diseases is vibrant. Ever more autoimmune diseases are being treated with CAR T cells, including rheumatologic, but also hematologic, neurologic, dermatologic and also gastroenterological diseases. This presentation will summarize novel developments including toxicities and toxicity management, expand on indications, discuss possible causes of shorter CAR T cell persistence, question immune reconstitution and functional consequences following CAR T, and will touch on mechanistic insights on how CAR T cells achieve responses, what happens in relapse, and if there are biomarkers that predict failure.
Speaker: Prof. Wing Leung, Director of the Children's Blood and Cancer Centre, KK Women's and Children's Hospital, Singapore and Prof. at Duke-NUS Medical School, Singapore
Allogeneic hematopoietic cell transplantations and CAR T cells are being increasingly used for the treatment of neoplastic and immune disorders. Despite remarkable progress, substantial unmet medical needs remain, including accessibility, adverse events, cost, and disease recurrence. In this lecture, Prof Leung will discuss his experience in solving these problems in the USA and in Asia by rapid successions of graft engineering and CAR T therapies facilitated by point-of-care manufacturing.
Speaker: Despina Eleftheriou, MD, UCL GOS Institute of Child Health, London, United Kingdom
Rare inflammatory disorders present a major therapeutic challenge, often leading to severe, progressive organ damage and limited treatment options. Advances in stem cell biology and gene editing technologies are opening new opportunities to address these unmet needs. This talk will outline current progress in developing stem cell–based gene therapies for monogenic autoinflammatory diseases. By combining hematopoietic stem cell transplantation with precise correction of pathogenic mutations, we aim to restore immune tolerance and halt tissue injury at its source.
I will discuss preclinical models demonstrating feasibility and safety, key translational hurdles – including vector design, engraftment, and long-term immune reconstitution – and strategies to overcome them. Early clinical studies highlight the promise of this approach to provide durable cures, while minimizing treatment toxicity compared with conventional therapies. Ultimately, stem cell gene therapy holds the potential to transform outcomes for patients with devastating inflammatory diseases that currently lack effective, curative treatments.
Speaker: Anna Pasetto, PhD, Oslo University Hospital, Center for Advanced Cell Therapy (ACT), Norway
Establishing academic pre-GMP and GMPcores is essential for translating advanced cell therapies from research to clinical application. This talk will explore the development of such infrastructures in Sweden and Norway, highlighting key lessons learned from planning, implementation, and regulatory navigation. Drawing from real-world experiences, it will address the unique challenges faced in the Nordic region, including securing funding, and fostering collaboration between academic institutions and healthcare providers.
Specific case studies will illustrate strategies for building scalable, compliant facilities while maintaining research flexibility.
Emphasis will be placed on overcoming operational hurdles, ensuring product quality, and facilitating the transition from preclinical development to first-in-human trials. This presentation aims to provide a practical roadmap for establishing academic GMP cores, offering insights that can guide similar initiatives across diverse regulatory and institutional landscapes.
Moderator: Rene Meißner, Miltenyi Biotec, Germany
Panelists:
Franco Locatelli, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany.
Wing Leung, MD, KK Women's and Children's Hospital, Singapore.
Despina Eleftheriou, MD, UCL GOS Institute of Child Health, London, United Kingdom.
Anna Pasetto, PhD, Oslo University Hospital, Center for Advanced Cell Therapy (ACT), Oslo, Norway.
Speaker: Natasha Kekre, MD, Ottawa Hospital Research Institute, Canada
Dr. Kekre will delve into the many unique challenges faced in the journey to offer CAR T cell therapy to patients across Canada, particularly those who may have otherwise run out of treatment options. Since its inception in 2016, the Canadian Led Immunotherapies Collaborative (CLIC) program has been at the forefront of this innovative treatment approach. By bringing together researchers, clinicians, and patients from across Canada, CLIC has focused on building expertise and expanding capacity for innovation in the rapidly evolving field of cellular immunotherapy.
The program's first clinical trial was launched in 2019, starting with two sites in Canada, but has since grown into a robust network encompassing multiple clinical and manufacturing sites across the country. In this presentation, Dr. Kekre will highlight the story behind the building of research capacity within CLIC, shedding light on the numerous trials and tribulations faced during the process of bringing a cell therapy product, manufactured on the CliniMACS Prodigy® Platform, to market authorization and standard of care in Canada.
Speaker: Nguyen Thanh Liem, MD, Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam
Purpose: This study aims to analyze the safety and primary efficacy of point-of-care CD19 CAR T cell therapy produced locally at low cost for the treatment of CD19+ B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in Vietnam.
Methods: A phase 1 clinical trial was conducted from August 2023 to March 2025. CD19 CAR T cells for 8 ALL patients and 8 NHL patients were manufactured using the automated CliniMACS Prodigy® System. CAR T cells were infused with doses ranging from 0.54 to 2.17×10^6 cells/kg.
Results: The number and percentage of CAR T cells at harvest were comparable between the 12-day and 8-day culture groups; however, viability was significantly better in the latter group (p=0.01). Upon treatment, the most common side effects included cytokine release syndrome (13 patients) and neurological toxicity (2 patients). No mortality related to CAR T therapy was observed. All ALL patients achieved complete remission after CAR T cell infusion on day 30. At 6 months, 5 patients (62.5%) remained in complete remission. 7 out of 8 NHL patients achieved complete remission on day 90, and 6 remained in complete remission at 6 months. One patient is awaiting assessment.
The total cost of CAR T cell therapy was approximately $140,000 per patient, with around $80,000 allocated to the CAR T product and $60,000 for treatment costs.
Conclusion: CD19 CAR T products can be produced at low cost. CAR T treatment is relatively safe and offers a promising therapeutic option for refractory/relapsed CD19+ NHL and ALL in a developing country like Vietnam.
Low cost CD19 CAR T can be produced for refractory/relapsed CD19+ NHL and ALL.
Speaker: Matjaz Sever, MD, University Clinical Center Ljubljana, Ljubljana, Slovenia
Chimeric antigen receptor (CAR) T cell therapy transformed hematologic cancer treatment, however, it faces barriers due to centralized, expensive manufacturing. Academic, point-of-care (PoC), and distributed models are faster and more affordable alternatives. PoC production near hospitals improves turnaround and cell quality, with platforms like the CliniMACS Prodigy® Platform achieving >85% success in 7–14 days. However, infrastructure, staffing, and regulatory problems persist. Distributed manufacturing scales PoC benefits across networks, requiring harmonized protocols and centralized vector sourcing.
Academic and PoC models show comparable safety and efficacy to commercial products, with costs as low as $35,000–$90,000 versus the range of $400,000 for commercial CAR T cell therapy. Accessibility remains uneven, but decentralized approaches may improve equity. Success depends on regulatory support, investment, and collaboration. Approach to PoC, academic CAR T cell program at UMC Ljubljana, Slovenia, will be presented in more detail.